We included all consecutive patients with VTE treated with VKA for > 90 days. We collected all variables included in the score (female sex, age < 60 years, medical history [> 2 comorbidities], treatment [interacting drugs: e.g. amiodarone], tobacco [doubled], race [doubled]) and analyzed the relationship between the SAMe-TT2R2 score and time in therapeutic range (TTR), determined by the Rosendaal method and by the percentage of INR determinations (after excluding the first month).
135 patients were treated with VKA for > 90 days, with a median TTR 65%. No differences in INR controls within range were found between patients with score 0–1 vs ≥ 2 (64.7 ± 19.5% vs 66.0 ± 20.5%, p = 0.728). No differences were found in INR controls above (21.5 ± 18.1% vs 21.2 ± 21.3%, p = 0.605) or below (3.9 ± 14% vs 2.9 ± 15.9%, p = 0.517) the therapeutic range.
The SAMe-TT2R2 score is not useful to predict quality of anticoagulation control in patients with VTE treated with VKA.